Trial Profile
A Phase II, Open Label, Single Arm Study of i.v. Panobinostat (LBH589) in Patients With Metastatic Hormone Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 09 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2010 Planned end date changed from 1 Mar 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 03 Jul 2009 Planned end date (Mar 2010) added as reported by ClinicalTrials.gov.